Cargando…
Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212727/ https://www.ncbi.nlm.nih.gov/pubmed/35728642 http://dx.doi.org/10.1016/j.jinf.2022.06.014 |
| _version_ | 1784730670861385728 |
|---|---|
| author | Niyomnaitham, Suvimol Toh, Zheng Quan Licciardi, Paul Vincent Wongprompitak, Patimaporn Srisutthisamphan, Kanjana Copeland, Katherine Kradangna Chokephaibulkit, Kulkanya |
| author_facet | Niyomnaitham, Suvimol Toh, Zheng Quan Licciardi, Paul Vincent Wongprompitak, Patimaporn Srisutthisamphan, Kanjana Copeland, Katherine Kradangna Chokephaibulkit, Kulkanya |
| author_sort | Niyomnaitham, Suvimol |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212727 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92127272022-06-22 Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial Niyomnaitham, Suvimol Toh, Zheng Quan Licciardi, Paul Vincent Wongprompitak, Patimaporn Srisutthisamphan, Kanjana Copeland, Katherine Kradangna Chokephaibulkit, Kulkanya J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-10 2022-06-18 /pmc/articles/PMC9212727/ /pubmed/35728642 http://dx.doi.org/10.1016/j.jinf.2022.06.014 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Niyomnaitham, Suvimol Toh, Zheng Quan Licciardi, Paul Vincent Wongprompitak, Patimaporn Srisutthisamphan, Kanjana Copeland, Katherine Kradangna Chokephaibulkit, Kulkanya Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial |
| title | Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial |
| title_full | Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial |
| title_fullStr | Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial |
| title_full_unstemmed | Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial |
| title_short | Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial |
| title_sort | immunogenicity of a single dose of bnt162b2, chadox1 ncov-19, or coronavac against sars-cov-2 delta and omicron variants among previously infected adults: a randomized trial |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212727/ https://www.ncbi.nlm.nih.gov/pubmed/35728642 http://dx.doi.org/10.1016/j.jinf.2022.06.014 |
| work_keys_str_mv | AT niyomnaithamsuvimol immunogenicityofasingledoseofbnt162b2chadox1ncov19orcoronavacagainstsarscov2deltaandomicronvariantsamongpreviouslyinfectedadultsarandomizedtrial AT tohzhengquan immunogenicityofasingledoseofbnt162b2chadox1ncov19orcoronavacagainstsarscov2deltaandomicronvariantsamongpreviouslyinfectedadultsarandomizedtrial AT licciardipaulvincent immunogenicityofasingledoseofbnt162b2chadox1ncov19orcoronavacagainstsarscov2deltaandomicronvariantsamongpreviouslyinfectedadultsarandomizedtrial AT wongprompitakpatimaporn immunogenicityofasingledoseofbnt162b2chadox1ncov19orcoronavacagainstsarscov2deltaandomicronvariantsamongpreviouslyinfectedadultsarandomizedtrial AT srisutthisamphankanjana immunogenicityofasingledoseofbnt162b2chadox1ncov19orcoronavacagainstsarscov2deltaandomicronvariantsamongpreviouslyinfectedadultsarandomizedtrial AT copelandkatherinekradangna immunogenicityofasingledoseofbnt162b2chadox1ncov19orcoronavacagainstsarscov2deltaandomicronvariantsamongpreviouslyinfectedadultsarandomizedtrial AT chokephaibulkitkulkanya immunogenicityofasingledoseofbnt162b2chadox1ncov19orcoronavacagainstsarscov2deltaandomicronvariantsamongpreviouslyinfectedadultsarandomizedtrial |